Compare TRIB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | CMMB |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 11.2M |
| IPO Year | 1996 | 2023 |
| Metric | TRIB | CMMB |
|---|---|---|
| Price | $0.62 | $1.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 236.8K | 45.6K |
| Earning Date | 03-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | ★ N/A | $42.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.87 |
| 52 Week High | $3.44 | $3.86 |
| Indicator | TRIB | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 49.87 |
| Support Level | $0.50 | $1.47 |
| Resistance Level | $0.80 | $1.85 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 48.61 | 38.71 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.